Emerging nanotechnology approaches for HIV/AIDS treatment and prevention

Nanomedicine

Volumn 5, Issue 2, 2010, Pages 269-285

  Mamo, Tewodros ^a,b   Moseman, E Ashley ^c   Kolishetti, Nagesh ^a,d   Salvador Morales, Carolina ^a,d   Shi, Jinjun ^a,d   Kuritzkes, Daniel R ^c   Langer, Robert ^d   Andrian, Ulrich Von ^c   Farokhzad, Omid C ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF WATERLOO   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

AIDS; Antiretroviral therapy; Gene therapy; HIV; Immunotherapy; Microbicides; Nanomedicine; Nanoparticles; Nanotechnology; Vaccines

Indexed keywords

ADJUVANT; ANTIRETROVIRUS AGENT; APTAMER; AZETIDINE; DENDRIMER; DNA; EFAVIRENZ; FULLERENE; GOLD NANOPARTICLE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LENTIVIRUS VECTOR; LIPOSOME; MACROGOL; MICROBICIDE; NANOMATERIAL; POLOXAMER; POLYGLACTIN; PROTEINASE INHIBITOR; RIBOZYME; RILPIVIRINE; SILVER NANOPARTICLE; SINGLE WALLED NANOTUBE; SMALL INTERFERING RNA; STAVUDINE; SURFACTANT; TUFTSIN; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-RETROVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; MALE; NANOMEDICINE; NANOTECHNOLOGY; RNA, SMALL INTERFERING;

EID: 77952488307     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.1     Document Type: Review

References (154)

1. Blattner W, Gallo RC, Temin HM: HIV causes AIDS. Science 241(4865), 515-516 (1988).
2. Gallo RC: Historical essay. The early years of HIV/AIDS. Science 298(5599), 1728-1730 (2002).
3. Gallo RC, Montagnier L: The discovery of HIV as the cause of AIDS. N. Engl. J. Med. 349(24), 2283-2285 (2003).
4. Montagnier L: Historical essay. A history of HIV discovery. Science 298(5599), 1727-1728 (2002).
5. Furin JJ, Behforouz HL, Shin SS et al.: Expanding global HIV treatment: Case studies from the feld. Ann. NY Acad. Sci. 1136, 12-20 (2008).
6. Merson MH: The HIV-AIDS pandemic at 25-the global response. N. Engl J. Med. 354(23), 2414-2417 (2006).
7. Joint United Nations Programme on HIV/AIDS: Report on the global HIV/AIDS epidemic. Joint United Nations Programme on HIV/AIDS. Geneva, Switzerland (2008).
8. Rodriguez-Monguio R, Seoane-Vazquez E: Patent life of antiretroviral drugs approved in the US from 1987 to 2007. AIDS Care 1-9 (2009).
9. Lang L: FDA grants tentative approval for 75th generic antiretroviral drug. Gastroenterology 136(1), 5 (2009).
10. Walensky R P, Paltiel AD, Losina E et al.: The survival benefts of AIDS treatment in the United States. J. Infect. Dis. 194(1), 11-19 (2006).
11. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ: The challenge of fnding a cure for HIV infection. Science 323(5919), 1304-1307 (2009).
12. Richman DD: HIV chemotherapy. Nature 410(6831), 995-1001 (2001).
13. Ledford H: Merck's HIV vaccine fop brings vectors under closer scrutiny. Nat. Biotechnol. 26(1), 3-4 (2008).
14. Ledford H: HIV vaccine developers battle on, despite high-profle failures. Nat. Biotechnol. 26(6), 591-592 (2008).
15. Uberla K: HIV vaccine development in the aftermath of the step study: Re-focus on occult HIV infection? PLoS Pathog. 4(8), e1000114 (2008).
16. Cohen J: Aids research. Microbicide fails to protect against HIV. Science 319(5866), 1026-1027 (2008).
17. Grant RM, Hamer D, Hope T et al.: Whither or wither microbicides? Science 321(5888), 532-534 (2008).
18. Farokhzad OC: Nanotechnology for drug delivery: The perfect partnership. Expert Opin. Drug Deliv. 5(9), 927-929 (2008).
19. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC: Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-769 (2008).
20. Ferrari M: Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 5(3), 161-171 (2005).
21. Nie S, Xing Y, Kim GJ, Simons JW: Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng. 9, 257-288 (2007).
22. Heath JR, Davis ME: Nanotechnology and cancer. Ann. Rev. Med. 59, 251-265 (2008).
23. Harrigan PR, Hogg RS, Dong WW et al.: Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis. 191(3), 339-347 (2005).
24. Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS: Re-emergence of HIV after stopping therapy. Nature 401(6756), 874-875 (1999).
25. Marsden MD, Zack JA: Eradication of HIV: Current challenges and new directions. J. Antimicrob. Chemother. 63(1), 7-10 (2009).
26. Sax PE, Cohen CJ, Kuritzkes DR: HIV Essentials. Physicians' Press, Royal Oak, MI, USA (2007).
27. Lamers SL, Salemi M, Galligan DC et al.: Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology. PLoS One 4(3), E5065 (2009).
28. McGee B, Smith N, Aweeka F: HIV pharmacology: Barriers to the eradication of HIV from the CNS. HIV Clin. Trials 7(3), 142-153 (2006).
29. Vyas TK, Shah L, Amiji MM: Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug Deliv. 3(5), 613-628 (2006).
30. Wan L, Pooyan S, Hu P, Leibowitz MJ, Stein S, Sinko PJ: Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted peg-fmlf (n-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharm. Res. 24(11), 2110-2119 (2007).
31. Nowacek A, Gendelman HE: Nanoart, neuroAIDS and CNS drug delivery. Nanomed. 4(5), 557-574 (2009).
32. Farokhzad OC, Langer R: Impact of nanotechnology on drug delivery. ACS Nano 3(1), 16-20 (2009).
33. Davis ME, Chen ZG, Shin DM: Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008).
34. Amiji MM, Vyas TK, Shah LK: Role of nanotechnology in HIV/AIDS treatment: Potential to overcome the viral reservoir challenge. Discov. Med. 6(34), 157-162 (2006).
35. Baert L, van't Klooster G, Dries W et al.: Development of a long-acting injectable formulation with nanoparticles of rilpivirine (tmc278) for HIV treatment. Eur. J. Pharm. Biopharm. 72(3), 502-508 (2009).
36. Dou H, Destache CJ, Morehead JR et al.: Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108(8), 2827-2835 (2006).
37. Dou H, Morehead J, Destache CJ et al.: Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358(1), 148-158 (2007).
38. Dou H, Grotepas CB, McMillan JM et al.: Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183(1), 661-669 (2009).
39. Garg M, Asthana A, Agashe HB, Agrawal GP, Jain NK: Stavudine-loaded mannosylated liposomes: In-vitro anti-HIV-i activity, tissue distribution and pharmacokinetics. J. Pharm. Pharmacol. 58(5), 605-616 (2006).
40. Garg M, Dutta T, Jain NK: Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur. J. Pharm. Biopharm. 67(1), 76-85 (2007).
41. Garg M, Garg BR, Jain S et al.: Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral effcacy of stavudine loaded 99mtc labeled galactosylated liposomes. Eur. J. Pharm. Sci. 33(3), 271-281 (2008).
42. Kaur CD, Nahar M, Jain NK: Lymphatic targeting of zidovudine using surface-engineered liposomes. J. Drug Target 16(10), 798-805 (2008).
43. Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, Jain NK: Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target 15(1), 89-98 (2007).
44. Dutta T, Jain NK: Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta 1770(4), 681-686 (2007).
45. Dutta T, Garg M, Jain NK: Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm. Sci. 34(2-3), 181-189 (2008).
46. Wan L, Zhang X, Pooyan S et al.: Optimizing size and copy number for PEG-FMLF (n-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages. Bioconjug. Chem. 19(1), 28-38 (2008).
47. Ganser-Pornillos BK, Yeager M, Sundquist WI: The structural biology of HIV assembly. Curr. Opin. Struct. Biol. 18(2), 203-217 (2008).
48. Pornillos O, Ganser-Pornillos BK, Kelly BN et al.: X-ray structures of the hexameric building block of the HIV capsid. Cell 137(7), 1282-1292 (2009).
49. Friedman SH, Decamp DL, Sijbesma R P, Srdanov G, Wudl F, Kenyon GL: Inhibition of the HIV-1 protease by fullerene derivatives-model-building studies and experimental-verifcation. J. Am. Chem. Soc. 115(15), 6506-6509 (1993).
50. Bosi S, Da Ros T, Spalluto G, Balzarini J, Prato M: Synthesis and anti-HIV properties of new water-soluble bis-functionalized[60] fullerene derivatives. Bioorg. Med. Chem. Lett. 13(24), 4437-4440 (2003).
51. Kotelnikova RA, Bogdanov GN, Frog EC et al.: Nanobionics of pharmacologically active derivatives of fullerene c-60. J. Nanopart. Res. 5(5-6), 561-566 (2003).
52. Marchesan S, Da Ros T, Spalluto G, Balzarini J, Prato M: Anti-HIV properties of cationic fullerene derivatives. Bioorg. Med. Chem. Lett. 15(15), 3615-3618 (2005).
53. Troshina OA, Troshin PA, Peregudov AS, Kozlovskiy VI, Balzarini J, Lyubovskaya RN: Chlorofullerene c60cl6: A precursor for straightforward preparation of highly water-soluble polycarboxylic fullerene derivatives active against HIV. Org. Biomol. Chem. 5(17), 2783-2791 (2007).
54. Durdagi S, Supuran CT, Strom TA et al.: In silico drug screening approach for the design of magic bullets: A successful example with anti-HIV fullerene derivatized amino acids. J. Chem. Inf. Model 49(5), 1139-1143 (2009).
55. Tanimoto S, Sakai S, Matsumura S, Takahashi D, Toshima K: Target-selective photo-degradation of HIV-1 protease by a fullerene-sugar hybrid. Chem. Commun. (44), 5767-5769 (2008).
56. Blanzat M, Turrin CO, Aubertin AM et al.: Dendritic catanionic assemblies: In vitro anti-HIV activity of phosphorus-containing dendrimers bearing gal beta(1)cer analogues. Chembiochem. 6(12), 2207-2213 (2005).
57. Wang W, Guo ZP, Chen Y, Liu T, Jiang L: Infuence of generation 2-5 of pamam dendrimer on the inhibition of tat peptide/tar rna binding in HIV-1 transcription. Chem. Biol. Drug Des. 68(6), 314-318 (2006).
58. Elechiguerra JL, Burt JL, Morones JR et al.: Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnology 3, 6 (2005).
59. Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM: Silver nanoparticles fabricated in hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem. Commun. (40), 5059-5061 (2005).
60. Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C: Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc. 130(22), 6896-6897 (2008).
61. Rossi JJ, June CH, Kohn DB: Genetic therapies against HIV. Nat. Biotechnol. 25(12), 1444-1454 (2007).
62. Haasnoot J, Westerhout EM, Berkhout B: Rna interference against viruses: strike and counterstrike. Nat. Biotechnol. 25(12), 1435-1443 (2007).
63. Li M, Rossi JJ: Lentiviral vector delivery of siRNA and shrna encoding genes into cultured and primary hematopoietic cells. Methods Mol. Biol. 433, 287-299 (2008).
64. Morris K V, Rossi JJ: Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther. 13(6), 553-558 (2006).
65. Li M, Li H, Rossi JJ: RNAI in combination with a ribozyme and tar decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann. NY Acad. Sci. 1082, 172-179 (2006).
66. Li MJ, Kim J, Li S et al.: Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shrna, anti-ccr5 ribozyme, and a nucleolar-localizing tar decoy. Mol. Ther. 12(5), 900-909 (2005).
67. Lee SK, Dykxhoorn DM, Kumar P et al.: Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood 106(3), 818-826 (2005).
68. Barnor JS, Miyano-Kurosaki N, Yamaguchi K, Abumi Y, Ishikawa K, Yamamoto N: Lentiviral-mediated delivery of combined HIV-1 decoy tar and VIF siRNA as a single rna molecule that cleaves to inhibit HIV-1 in transduced cells. Nucleosides Nucleotides Nucleic Acids 24(5-7), 431-434 (2005).
69. + cells. Nat. Med. 15(3), 285-292 (2009).
70. Mintzer MA, Simanek EE: Nonviral vectors for gene delivery. Chem. Rev. 109(2), 259-302 (2009).
71. Lundin KE, Simonson OE, Moreno PM et al.: Nanotechnology approaches for gene transfer. Genetica 137(1), 47-56 (2009).
72. Gao X, Kim KS, Liu DX: Nonviral gene delivery: What we know and what is next. AAPS J. 9(1), E92-E104 (2007).
73. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specifc genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 391(6669), 806-811 (1998). (Pubitemid 28099681)
74. Whitehead KA, Langer R, Anderson DG: Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
75. Berkhout B, ter Brake O: Towards a durable rnai gene therapy for HIV-AIDS. Expert Opin. Biol. Ther. 9(2), 161-170 (2009).
76. Davis ME: The frst targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharm. 6(3), 659-668 (2009).
77. Eguchi A, Meade BR, Chang YC et al.: Effcient siRNA delivery into primary cells by a peptide transduction domain-dsrna binding domain fusion protein. Nat. Biotechnol. 27(6), 567-571 (2009).
78. Song E, Zhu P, Lee SK et al.: Antibody mediated in vivo delivery of small interfering rnas via cell-surface receptors. Nat. Biotechnol. 23(6), 709-717 (2005).
79. Liu Z, Winters M, Holodniy M, Dai H: Sirna delivery into human t cells and primary cells with carbon-nanotube transporters. Angew. Chem. Int. Ed. 46(12), 2023-2027 (2007).
80. Weber N, Ortega P, Clemente MI et al.: Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Control Release 132(1), 55-64 (2008).
81. Kumar P, Ban HS, Kim SS et al.: T cell-specifc siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134(4), 577-586 (2008).
82. Kumar P, Wu HQ, McBride JL et al.: Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39-43 (2007).
83. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes B: The immune response during acute HIV-1 infection: Clues for vaccine development. Nat. Rev. Immunol. (2009).
84. Pett SL: Immunotherapies in HIV-1 infection. Curr. Opin. HIV AIDS 4(3), 188-193 (2009).
85. Gandhi RT, Walker BD: Immunologic control of HIV-1. Ann. Rev. Med. 53, 149-172 (2002).
86. Cohen J: Building an HIV-proof immune system. Science 317(5838), 612-614 (2007).
87. Rinaldo CR: Dendritic cell-based human immunodefciency virus vaccine. J. Intern. Med. 265(1), 138-158 (2009).
88. Banchereau J, Briere F, Caux C et al.: Immunobiology of dendritic cells. Ann. Rev. Immunol. 18, 767-811 (2000).
89. Shortman K, Liu YJ: Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2(3), 151-161 (2002).
90. Bourinbaiar AS, Root-Bernstein RS, Abulafa-Lapid R et al.: Therapeutic AIDS vaccines. Curr. Pharm. Des. 12(16), 2017-2030 (2006).
91. Dorrell L, Williams P, Suttill A et al.: Safety and tolerability of recombinant modifed vaccinia virus ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25(17), 3277-3283 (2007).
92. Gandhi RT, O'Neill D, Bosch RJ et al.: A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. Canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 27(43), 6088-6094 (2009).
93. Whiteside TL, Piazza P, Reiter A et al.: Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodefciency virus type 1 infection. Clin. Vaccine Immunol. 16(2), 233-240 (2009).
94. Tacken PJ, de Vries IJM, Torensma R, Figdor CG: Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007).
95. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA: In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfde) nanoparticles. J. Control Release 112(1), 26-34 (2006).
96. Hori Y, Winans AM, Huang CC, Horrigan EM, Irvine DJ: Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials 29(27), 3671-3682 (2008).
97. Elamanchili P, Diwan M, Cao M, Samuel J: Characterization of poly(d,l-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22(19), 2406-2412 (2004).
98. Aline F, Brand D, Pierre J et al.: Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic pla nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 27(38), 5284-5291 (2009).
99. Lori F, Calarota SA, Lisziewicz J: Nanochemistry-based immunotherapy for HIV-1. Curr. Med. Chem. 14(18), 1911-1919 (2007).
100. Bass E, Feuer C, Warren M: Aids vaccine research and advocacy: An update. BETA 21(2), 24-30 (2009).
101. Jefferys R: Vaccine failure is not a 'crisis' for HIV research. Nature 453(7196), 719-720 (2008).
102. Barouch DH: Challenges in the development of an HIV-1 vaccine. Nature 455(7213), 613-619 (2008).
103. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S: Antigen presentation and t cell stimulation by dendritic cells. Ann. Rev. Immunol. 20, 621-667 (2002).
104. Trombetta ES, Mellman I: Cell biology of antigen processing in vitro and in vivo. Ann. Rev. Immunol. 23, 975-1028 (2005).
105. McHeyzer-Williams LJ, McHeyzer-Williams MG: Antigen-specifc memory b cell development. Ann. Rev. Immunol. 23, 487-513 (2005).
106. Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM: Design opportunities for actively targeted nanoparticle vaccines. Nanomed. 3(3), 343-355 (2008).
107. Csaba N, Garcia-Fuentes M, Alonso MJ: Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev. 61(2), 140-157 (2009).
108. Sakaue G, Hiroi T, Nakagawa Y et al.: HIV mucosal vaccine: Nasal immunization with gp160-encapsulated hemagglutinating virus of japan-liposome induces antigen-specifc ctls and neutralizing antibody responses. J. Immunol. 170(1), 495-502 (2003).
109. Singh SK, Bisen PS: Adjuvanticity of stealth liposomes on the immunogenicity of synthetic gp41 epitope of HIV-1. Vaccine 24(19), 4161-4166 (2006).
110. Wagner A, Stiegler G, Vorauer-Uhl K et al.: One step membrane incorporation of viral antigens as a vaccine candidate against HIV. J. Liposome Res. 17(3-4), 139-154 (2007).
111. Watson DS, Huang Z, Szoka FC Jr: All-trans retinoic acid potentiates the antibody response in mice to a lipopeptide antigen adjuvanted with liposomal lipid a. Immunol. Cell Biol. (2009).
112. Letvin NL: Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 6(12), 930-939 (2006).
113. Burton DR, Desrosiers RC, Doms RW et al.: HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5(3), 233-236 (2004).
114. Takeda K, Kaisho T, Akira S: Toll-like receptors. Ann. Rev. Immunol. 21, 335-376 (2003).
115. Fairman J, Moore J, Lemieux M et al.: Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum. Vaccin. 5(2), (2008).
116. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G: Mf59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277-296 (1995).
117. Copland MJ, Rades T, Davies NM, Baird MA: Lipid based particulate formulations for the delivery of antigen. Immunol. Cell. Biol. 83(2), 97-105 (2005).
118. Tritto E, Mosca F, De Gregorio E: Mechanism of action of licensed vaccine adjuvants. Vaccine 27(25-26), 3331-3334 (2009).
119. Leung L, Srivastava IK, Kan E et al.: Immunogenicity of HIV-1 env and gag in baboons using a DNA prime/protein boost regimen. AIDS 18(7), 991-1001 (2004).
120. Brave A, Hinkula J, Cafaro A et al.: Candidate HIV-1 gp140dv2, gag and tat vaccines protect against experimental HIV-1/MULV challenge. Vaccine 25(39-40), 6882-6890 (2007).
121. Burke B, Gomez-Roman VR, Lian Y et al.: Neutralizing antibody responses to subtype b and c adjuvanted HIV envelope protein vaccination in rabbits. Virology 387(1), 147-156 (2009).
122. Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefori DC, Baker JR Jr: Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 24(2), 271-281 (2008).
123. Ataman-Onal Y, Munier S, Ganee A et al.: Surfactant-free anionic pla nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J. Control Release 112(2), 175-185 (2006).
124. Lamalle-Bernard D, Munier S, Compagnon C et al.: Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic pla nanoparticles preserves antigenicity and immunogenicity. J. Control Release 115(1), 57-67 (2006).
125. Guillon C, Mayol K, Terrat C et al.: Formulation of HIV-1 tat and p24 antigens by pla nanoparticles or mf59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 25(43), 7491-7501 (2007).
126. Miyake A, Akagi T, Enose Y et al.: Induction of HIV-specifc antibody response and protection against vaginal sHIV transmission by intranasal immunization with inactivated sHIV-capturing nanospheres in macaques. J. Med. Virol. 73(3), 368-377 (2004).
127. Kawamura M, Wang X, Uto T et al.: Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice. J. Med. Virol. 76(1), 7-15 (2005).
128. Akagi T, Wang X, Uto T, Baba M, Akashi M: Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 28(23), 3427-3436 (2007).
129. + T-cell responses by novel biodegradable nanoparticles carrying human immunodefciency virus type 1 gp120. J. Virol. 81(18), 10009-10016 (2007).
130. Wang X, Uto T, Akagi T, Akashi M, Baba M: Poly(gamma-glutamic acid) nanoparticles as an effcient antigen delivery and adjuvant system: Potential for an AIDS vaccine. J. Med. Virol. 80(1), 11-19 (2008).
131. Stoneburner RL, Low-Beer D: Population-level HIV declines and behavioral risk avoidance in uganda. Science 304(5671), 714-718 (2004).
132. Rohan LC, Sassi AB: Vaginal drug delivery systems for HIV prevention. AAPS J. 11(1), 78-87 (2009).
133. Saidi H: Microbicides: An emerging science of HIV-1 prevention in women-15th conference on retroviruses and opportunistic infections, boston, USA, 3-6 February 2008. Rev. Med. Virol. 19(2), 69-76 (2009).
134. das Neves J, Bahia MF: Gels as vaginal drug delivery systems. Int. J. Pharm. 318(1-2), 1-14 (2006).
135. Klasse PJ, Shattock R, Moore JP: Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Ann. Rev. Med. 59, 455-471 (2008).
136. Rupp R, Rosenthal SL, Stanberry LR: Vivagel (spl7013 gel): A candidate dendrimer-microbicide for the prevention of HIV and hsv infection. Int. J. Nanomedicine 2(4), 561-566 (2007).
137. McCarthy TD, Karellas P, Henderson SA et al.: Dendrimers as drugs: Discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2(4), 312-318 (2005).
138. Jiang YH, Emau P, Cairns JS et al.: Spl7013 gel as a topical microbicide for prevention of vaginal transmission of sHIV89.6p in macaques. AIDS Res. Hum. Retroviruses 21(3), 207-213 (2005).
139. Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC: Targeted delivery of psc-rantes for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 26(3), 502-511 (2009).
140. Lederman MM, Veazey RS, Offord R et al.: Prevention of vaginal sHIV transmission in rhesus macaques through inhibition of ccr5. Science 306(5695), 485-487 (2004).
141. Palliser D, Chowdhury D, Wang QY et al.: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439(7072), 89-94 (2006).
142. Rossi JJ: Topical antiviral siRNA: A practical siRNA microbicide? Gene Ther. 13(21), 1493-1494 (2006).
143. Wu Y, Navarro F, Lal A et al.: Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell. Host Microbe 5(1), 84-94 (2009).
144. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM: Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater. 8(6), 526-533 (2009).
145. Zhang LF, Chan JM, Gu FX et al.: Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano 2(8), 1696-1702 (2008).
146. Zhang LF, Radovic-Moreno AF, Alexis F et al.: Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem. Med. Chem. 2(9), 1268-1271 (2007).
147. Wang Y, Gao SJ, Ye WH, Yoon HS, Yang YY: Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 5(10), 791-796 (2006).
148. Lee ALZ, Wang Y, Cheng HY, Pervaiz S, Yang YY: The co-delivery of paclitaxel and herceptin using cationic micellar nanoparticles. Biomaterials 30(5), 919-927 (2009).
149. Shacklett BL: Can the new humanized mouse model give HIV research a boost. PLoS Med. 5(1), e13 (2008).
150. Shultz LD, Ishikawa F, Greiner DL: Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7(2), 118-130 (2007).
151. Damge C, Reis CP, Maincent P: Nanoparticle strategies for the oral delivery of insulin. Expert Opin. Drug Del. 5(1), 45-68 (2008).
152. Lai SK, Wang YY, Hanes J: Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Del. Rev. 61(2), 158-171 (2009).
153. Tang BC, Dawson M, Lai SK et al.: Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl Acad. Sci. USA 106(46), 19268-19273 (2009).
154. Xing JF, Deng LD, Li J, Dong AJ: Amphiphilic poly{[a-maleic anhydride-omega-methoxy-poly(ethylene glycol)]-co-(ethyl cyanoacrylate)} graft copolymer nanoparticles as carriers for transdermal drug delivery. Int. J. Nanomedicine 4, 227-232 (2009).